Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Structure and Function of Platelets01:18

Structure and Function of Platelets

The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000 platelets, with...
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Intracellular Signaling Affects Focal Adhesions01:17

Intracellular Signaling Affects Focal Adhesions

Integrins act both as extracellular input receivers and as intracellular processing activators. As their name suggests, integrins are entirely integrated into the membrane structure. Their hydrophobic membrane-spanning regions interact with the phospholipid bilayer's hydrophobic region. These membrane receptors provide extracellular attachment sites for effectors like hormones and growth factors. They activate intracellular response cascades when their effectors are bound and active.
Some...
Phosphoinositides and PIPs01:42

Phosphoinositides and PIPs

Phosphoinositides are a group of phospholipids containing a glycerol backbone with two fatty acid chains and a phosphate attached to a myoinositol sugar ring. The inositol head group extends into the cytoplasm, where it is modified by adding phosphate groups to form phosphatidylinositol phosphates or PIPs.
Different phosphoinositides are synthesized and recruited on the cytosolic face of the plasma membrane. The localization of specific phosphoinositides concentrated in separate membrane...
GPI Anchoring of Proteins in the ER Membrane01:29

GPI Anchoring of Proteins in the ER Membrane

GPI-anchoring is a post-translational, reversible protein modification that is ubiquitous in eukaryotes. Such proteins are primarily present on the exoplasmic leaflet of the plasma membrane.
GPI-anchor structure
A sequence of 11 enzymatic reactions results in the synthesis of the complete GPI anchor consisting of a hydrophobic and a hydrophilic portion. The hydrophobic portion comprises phosphatidylinositol, while the hydrophilic part comprises polar groups like phosphoethanolamine,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Responsiveness and Minimal Important Change of the Haemophilia Activities List in Patients With Inherited Bleeding Disorders.

Haemophilia : the official journal of the World Federation of Hemophilia·2026
Same author

Postpartum well-being in hemophilia carriers and women with von Willebrand disease: insights from patient-reported outcome measures.

Research and practice in thrombosis and haemostasis·2026
Same author

Comparative phenotyping of surface markers and glycans in murine and human platelet-derived extracellular vesicles.

Research and practice in thrombosis and haemostasis·2026
Same author

Intermediate dose heparin thromboprophylaxis among critically ill patients with COVID-19: a randomized clinical trial.

Journal of thrombosis and haemostasis : JTH·2026
Same author

Thrombin generation and thrombin dynamics are associated with recurrent venous thromboembolism after anticoagulation withdrawal.

Journal of thrombosis and haemostasis : JTH·2026
Same author

The use of light transmission aggregometry for monitoring platelet transfusion response in a small case cohort of Glanzmann thrombasthenia patients: a hypothesis-generating study.

Platelets·2026

Related Experiment Video

Updated: Jun 15, 2026

An In Vitro Assay to Study Platelet Migration Using RGD-Functionalized Avidin-Biotin Tethers
05:43

An In Vitro Assay to Study Platelet Migration Using RGD-Functionalized Avidin-Biotin Tethers

Published on: November 8, 2024

Role of glycoprotein Ibalpha mobility in platelet function.

Dianne E van der Wal1, Sandra Verhoef, Roger E G Schutgens

  • 1Department of Clinical Chemistry and Haematology, University Medical Centre Utrecht, Utrecht, The Netherlands.

Thrombosis and Haemostasis
|March 11, 2010
PubMed
Summary

Cold storage and rewarming of platelets expose N-acetyl-D-glucosamine on glycoprotein (GP) Ibalpha, triggering platelet activation. This conformational change in GP Ibalpha

More Related Videos

A Uniform Shear Assay for Human Platelet and Cell Surface Receptors via Cone-plate Viscometry
04:32

A Uniform Shear Assay for Human Platelet and Cell Surface Receptors via Cone-plate Viscometry

Published on: June 5, 2019

Platelet Adhesion and Aggregation Under Flow using Microfluidic Flow Cells
10:10

Platelet Adhesion and Aggregation Under Flow using Microfluidic Flow Cells

Published on: October 27, 2009

Related Experiment Videos

Last Updated: Jun 15, 2026

An In Vitro Assay to Study Platelet Migration Using RGD-Functionalized Avidin-Biotin Tethers
05:43

An In Vitro Assay to Study Platelet Migration Using RGD-Functionalized Avidin-Biotin Tethers

Published on: November 8, 2024

A Uniform Shear Assay for Human Platelet and Cell Surface Receptors via Cone-plate Viscometry
04:32

A Uniform Shear Assay for Human Platelet and Cell Surface Receptors via Cone-plate Viscometry

Published on: June 5, 2019

Platelet Adhesion and Aggregation Under Flow using Microfluidic Flow Cells
10:10

Platelet Adhesion and Aggregation Under Flow using Microfluidic Flow Cells

Published on: October 27, 2009

Area of Science:

  • Hematology
  • Immunology
  • Biochemistry

Background:

  • Cold exposure of platelets reveals N-acetyl-D-glucosamine on glycoprotein (GP) Ibalpha, leading to receptor clustering and macrophage-mediated platelet destruction.
  • Understanding GP Ibalpha conformational changes is crucial for platelet storage and transfusion outcomes.

Purpose of the Study:

  • To investigate the conformational changes of GP Ibalpha induced by a clinically relevant cold storage and rewarming protocol (0/37°C).
  • To determine the role of these conformational changes in platelet function, including aggregation, spreading, and activation.

Main Methods:

  • Incubation of platelets at 0°C followed by 37°C.
  • Antibody binding assays to detect GP Ibalpha conformational changes.
  • Assessment of platelet aggregation, agglutination, and spreading under flow conditions.
  • Measurement of thromboxane A(2) formation in wild-type and deficient platelets.

Main Results:

  • Incubation at 0/37°C induced a conformational change in the N-terminal flank (NTF) of GP Ibalpha, but not in other regions.
  • N-acetyl-D-glucosamine addition inhibited the 0/37°C-induced responses.
  • The NTF conformational change was associated with GP Ibalpha shifting to the cytoskeleton and supported VWF/ristocetin-induced agglutination and spreading.
  • Crucially, 0/37°C incubation initiated thromboxane A(2) formation independently of VWF but dependent on GP Ibalpha.

Conclusions:

  • The 0/37°C-induced NTF conformational change in GP Ibalpha reflects receptor clustering.
  • This conformational change supports VWF-mediated platelet functions like agglutination and spreading.
  • The NTF change is sufficient to initiate platelet activation and thromboxane A(2) production, even without VWF.